20:36 , Aug 7, 2019 |  BC Extra  |  Financial News

Glycomine looks toward clinic with Novo-led $33M round

Glycomine raised a tranched $33 million series B round to take its lead rare congenital disease therapy into the clinic. Novo Holdings A/S led the round. Additional new investors Asahi Kasei Pharma Corp. and Mission...
22:15 , Jun 17, 2019 |  BC Extra  |  Company News

Trial data suggest 80% of Zynteglo patients could meet milestones in outcomes-based pricing model

The most recent long-term data for bluebird bio's Zynteglo β thalassemia gene therapy show that about 80% of patients could hit payment milestones based on details the biotech disclosed about its outcomes-based pricing model on...
00:12 , Jun 7, 2019 |  BC Extra  |  Company News

June 6 Company Quick Takes: Take two for Celgene's ozanimod; plus Protalix, ABPI, Axovant and Mylan

Celgene resubmits NDA for ozanimod   FDA and EMA accepted submissions from Celgene Corp. (NASDAQ:CELG) for ozanimod to treat multiple sclerosis. The PDUFA date for the selective S1PR1 and S1PR5 modulator is March 25, 2020,...
22:20 , May 31, 2019 |  BC Extra  |  Company News

May 31 Company Quick Takes: NMPA accepts two BeiGene applications, approves Hengrui's PD-1 inhibitor; and more

NMPA accepts applications for BeiGene's tislelizumab, Abraxane  China's National Medical Products Administration has accepted an sNDA from BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) for tislelizumab to treat previously treated, locally advanced or metastatic urothelial carcinoma. The anti-PD-1...
22:37 , May 30, 2019 |  BC Extra  |  Company News

May 30 Company Quick Takes: Unity in-licenses protein for cognitive decline, plus Astellas, Organovo, Iovance

Unity in-licenses UCSF protein for cognitive improvement  Unity Biotechnology Inc. (NASDAQ:UBX) licensed from the University of California San Francisco exclusive, worldwide rights to IP relating to KLA, including its use to reverse or prevent cognitive...
23:44 , May 23, 2019 |  BC Extra  |  Company News

May 23 Company Quick Takes: Chiesi gains Raxone rights; plus WuXi Vaccines, a Zika first and more

Chiesi gains rights to Santhera's Raxone for LHON  Santhera Pharmaceuticals Holding AG (SIX:SANN) granted Chiesi Farmaceutici S.p.A. (Parma, Italy) exclusive, worldwide rights outside of the U.S. and Canada to Raxone idebenone for Leber hereditary optic...
23:54 , May 8, 2019 |  BC Extra  |  Company News

May 8 Company Quick Takes: Takeda selling Shire eye drug to Novartis in $3.4B deal; plus BioNTech, Third Rock’s Thrive and more

Takeda off-loads Xiidra, TachoSil  Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) will sell Xiidra lifitegrast to Novartis AG (NYSE:NVS; SIX:NOVN) for $3.4 billion up front, plus $1.9 billion in milestones. Takeda said divesting the dry eye...
16:29 , Apr 2, 2019 |  BC Extra  |  Financial News

Ocular oncology play Aura raises $40M D round

Medicxi led a $40 million series D round for Aura as the ocular oncology company prepares its lead choroidal melanoma therapy for Phase III testing in 1H20. The funding will give Aura Biosciences Inc. (Cambridge,...
17:32 , Jan 17, 2019 |  BC Week In Review  |  Company News

TiumBio grants Chiesi rights to develop TGF-β molecules to treat respiratory diseases

TiumBio Co. Ltd. (Seongnam, South Korea) granted Chiesi Farmaceutici S.p.A. (Parma, Italy) exclusive, worldwide rights to develop and commercialize small molecules targeting transforming growth factor beta (TGF-β) signaling. The partners said the deal covers respiratory...
17:26 , Jan 11, 2019 |  BC Week In Review  |  Clinical News

CereSpir's itanapraced reduces neurotoxicity in PD model

CereSpir Inc. (New York, N.Y.) reported on Dec. 10 that lead product itanapraced (CSP-1103) reduced neurotoxicity in a mouse model of Parkinson’s disease and in cultured neurons from the model. The company said the data...